Navigation Links
FDA approves HeartMate II mechanical heart pump for heart-failure patients
Date:5/2/2008

NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate II LVAS (Left Ventricular Assist System) -- a miniature mechanical pump that helps weak hearts pump blood -- that has now received approval by the FDA as of April 21 for broad use as bridge to transplantation. As part of clinical trials leading to approval, 22 patients received the new device at NewYork-Presbyterian/Columbia -- more than any other hospital in the New York area.

Clinical research studies at medical centers, including NewYork-Presbyterian/Columbia, showed the HeartMate II to be safe and effective, with improved quality of life and survival compared with historical norms for heart-failure patients. In addition, the device is designed to be quieter and more durable than other FDA approved devices.

One-eighth the size of the original HeartMate LVAS, the HeartMate II provides continuous blood flow through the circulatory system using only one moving part -- a rotary pumping mechanism.

"For patients whose hearts are unable to effectively pump blood due to severe heart failure, this remarkable device can help them have active lives as they await a heart transplant," says Dr. Yoshifumi Naka, principal investigator of the clinical research studies and director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of surgery at Columbia University College of Physicians and Surgeons.

With around 2,200 donor hearts available annually, there are large numbers of patients with end-stage heart failure placed on heart transplant waiting lists. These patients would be candidates to receive the HeartMate II LVAS as a therapeutic option to sustain them until transplant.

FDA approval was based on one-year follow-up data from the first 194 HeartMate II patients enrolled in the trial. Highlights included:

  • Survival to cardiac transplantation, recovery or ongoing on HeartMate II support was 80 percent at six months and 77 percent at one year.

  • Eighty-four percent of the patients survived to hospital discharge or transplantation.

  • The incidence of major adverse events with comparable definitions -- including infections, strokes and bleeding requiring surgery -- was significantly lower than what was clinically observed in the previous bridge-to-transplantation study of the HeartMate VE LVAS (HeartMate IIs predecessor).

Currently, NewYork-Presbyterian Hospital/Columbia University Medical Center is participating in a clinical trial of HeartMate II as a long-term therapy (also known as destination therapy) that could potentially also serve as a permanent support option for these patients.


'/>"/>

Contact: Belinda Mager
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
2. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
3. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
4. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
5. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
6. VeriPrime Approves New Best Practices for Beef Production
7. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
8. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries
9. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
10. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
11. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... From a health perspective, 2017 will clearly be ... health to chronic disease, mental health and general physical well-being. The New York Times ... to consider. , For one Charlottesville restaurant, good gut health is clearly on the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... leading journal and most-read publication among specialty pharmacists and pharmacy professionals, has ... its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of Pharmacy ...
(Date:1/18/2017)... Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... as a fund raiser for Smile Train, an international charity that provides free surgery ... a hobby of mine and in the past I have run to support the ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... The Portee ... to families and business owners in central Maryland and the DC region, is inaugurating ... disease kills 787,000 people nationally every year, making it the #1 killer in America. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Regenicin, ... a biotechnology company specializing in the development and commercialization ... damaged tissues and organs, recently reported the Company,s operating ... for 2017. As the Company described in ... been a year of substantial accomplishments. The Company,s contract ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017 /PRNewswire/ ... líderes lanzaron Access Accelerated, una iniciativa global para avanzar ... (NCD) y atención en países de renta baja y ... han alcanzado un punto de crisis, particularmente en países ... el 80 por ciento de las muertes relacionadas con ...
Breaking Medicine Technology: